ArticleGastrointestinal endoscopy2025
Burden and cost of post-endoscopic retrograde cholangiopancreatography pancreatitis among commercially insured people undergoing endoscopic retrograde cholangiopancreatography.
Article in Gastrointestinal endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis: Implications for Severity and Cost.Digestive diseases and sciences · 2026Article
- Use of the self-assembling peptide (PuraStat™) for the management and prevention of ERCP-related bleeding: a multicenter prospective cohort study.Surgical endoscopy · 2026Observational
- Variations in Incidence and Financial Burdens of Nonpancreatic Postendoscopic Retrograde Cholangiopancreatography Adverse Events.Clinical and translational gastroenterology · 2026Article
- Comparative outcomes and characteristics of biliary, alcoholic and drug-induced pancreatitis based on the National Inpatient Sample (2016-2021).Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsERCP is the primary therapeutic procedure for pancreaticobiliary diseases. Post-ERCP pancreatitis can occur in up to 10% to 15% of cases; however, very little data describe the incidence and financial burden of post-ERCP pancreatitis in a nationally representative sample in the United States. In this study, we characterized the 30-day incidence of post-ERCP pancreatitis, identified patient- and procedure-related factors associated with post-ERCP pancreatitis, and described 30-day direct and out-of-pocket (OOP) costs among patients with post-ERCP pancreatitis.
methodsWe used the Merative MarketScan commercial claims data to identify inpatient and outpatient ERCPs occurring from 2019 to 2021. The primary outcome was the development of post-ERCP pancreatitis within 30 days of an ERCP. The main measure of financial burden was the total direct and OOP costs of the index ERCP and all encounters within 30 days after the index ERCP. We used multivariable regression to identify factors and estimate adjusted costs of post-ERCP pancreatitis.
resultsAmong 27,482 patients who underwent 42,212 ERCPs during the study period, post-ERCP pancreatitis was observed in 5.7% of patients. In multivariable analysis, the highest odds of post-ERCP pancreatitis was observed among the youngest age group (≤17 years) undergoing ERCP (odds ratio, 1.53; 95% CI, 1.06-2.21). The 30-day adjusted mean direct costs among persons with and without post-ERCP pancreatitis were $38,569 and $30,103, respectively (difference, $8483). The population-level cost of post-ERCP pancreatitis ranged from $85,833,757 to $432,648,810 across a range of reported estimates for post-ERCP pancreatitis and annual ERCP volume in the United States.
conclusionsPost-ERCP pancreatitis is relatively uncommon, occurring in 5% to 6% of individuals, but results in substantial financial burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.